GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Usana Health Sciences Inc (NYSE:USNA) » Definitions » Cash Flow from Operations

USNA (Usana Health Sciences) Cash Flow from Operations : $58.8 Mil (TTM As of Mar. 2025)


View and export this data going back to 1993. Start your Free Trial

What is Usana Health Sciences Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2025, Usana Health Sciences's Net Income From Continuing Operations was $9.3 Mil. Its Depreciation, Depletion and Amortization was $10.2 Mil. Its Change In Working Capital was $-9.5 Mil. Its cash flow from deferred tax was $1.4 Mil. Its Cash from Discontinued Operating Activities was $0.0 Mil. Its Asset Impairment Charge was $1.2 Mil. Its Stock Based Compensation was $2.9 Mil. And its Cash Flow from Others was $0.0 Mil. In all, Usana Health Sciences's Cash Flow from Operations for the three months ended in Mar. 2025 was $15.5 Mil.


Usana Health Sciences Cash Flow from Operations Historical Data

The historical data trend for Usana Health Sciences's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Usana Health Sciences Cash Flow from Operations Chart

Usana Health Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 160.40 121.23 103.90 70.64 60.99

Usana Health Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.68 7.99 29.53 5.79 15.48

Usana Health Sciences Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Usana Health Sciences's Cash Flow from Operations for the fiscal year that ended in Dec. 2024 is calculated as:

Usana Health Sciences's Cash Flow from Operations for the quarter that ended in Mar. 2025 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $58.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Usana Health Sciences  (NYSE:USNA) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Usana Health Sciences's net income from continuing operations for the three months ended in Mar. 2025 was $9.3 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Usana Health Sciences's depreciation, depletion and amortization for the three months ended in Mar. 2025 was $10.2 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Usana Health Sciences's change in working capital for the three months ended in Mar. 2025 was $-9.5 Mil. It means Usana Health Sciences's working capital declined by $9.5 Mil from Dec. 2024 to Mar. 2025 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Usana Health Sciences's cash flow from deferred tax for the three months ended in Mar. 2025 was $1.4 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Usana Health Sciences's cash from discontinued operating Activities for the three months ended in Mar. 2025 was $0.0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Usana Health Sciences's asset impairment charge for the three months ended in Mar. 2025 was $1.2 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Usana Health Sciences's stock based compensation for the three months ended in Mar. 2025 was $2.9 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Usana Health Sciences's cash flow from others for the three months ended in Mar. 2025 was $0.0 Mil.


Usana Health Sciences Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Usana Health Sciences's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Usana Health Sciences Business Description

Traded in Other Exchanges
Address
3838 West Parkway Boulevard, Salt Lake City, UT, USA, 84120
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
Executives
Brent Neidig officer: CO & Man. Dir. of China 3838 WEST PARKWAY BLVD., WEST VALLEY CITY UT 84120
Joshua Foukas officer: Chief Legal Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY X1 84120
John Turman Fleming director 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
David Mulham Mulham officer: Chief Field Development Office 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Gilbert A Fuller officer: CFO and Executive V.P. 55 WANDERWOOD WAY, SANDY UT 84092
Jim Brown officer: Chief Production Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Peggie Pelosi director 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84111
Paul A. Jones officer: CFO 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Myron W Wentz director 3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120
G Doug Iiekking officer: VP of Finance C/O USANA HEALTH SCIENCES INC, 3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120
Daniel A. Macuga officer: Chief Communications Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Kevin Guest officer: E.V.P. of Marketing 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Walter Noot officer: Chief Information Officer 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Robert A Sinnott officer: Chief Scientific Officer 400 55 WATER STREET, VANCOUVER A1 V6B1A1
Frederic J Winssinger director 2944 N 44TH STREET, SUITE 250, PHOENIX AZ 85018